Latest Industry Insights

In this interview, Technology Networks spoke to Heiko Neuweger, director of Bioinformatics Life Science Mass Spectrometry Software R&D at Bruker, to learn about the importance of target compound annotation and identification, the advantages of integrating collision cross section (CCS) information into workflows and the benefits of CCS-Predict Pro.

Join us for an interview with HP's Christie Dudenhoefer, manager of Life Science Solutions, and Dr. Ryan Kelly, professor in the Department of Chemistry at Brigham Young University, to learn how HP's D100 single-cell dispenser is being utilized.

With growing sustainability demands, companies are looking for ways to demonstrate their green credentials. We spoke to Dr. Michael Frank to find out what ACT accreditation means for a company and why he thinks schemes like this are so important.

HPLC system manufacturers have been striving to improve usability, accessibility and help users improve their experimental outcomes. And what better way to do that than to involve the users themselves in that development process.

We spoke with Bio-Rad’s Justin Barker to discover some of the challenges associated with gene expression analysis in oncology and learn about technology developments in this field.

We spoke to Prof. Oscar Ces, head of the Department of Chemistry at Imperial College London (ICL), to find out about the evolution of ICL’s White City Campus, the Agilent Measurement Suite and what it means for scientists across the board.

Cutting-edge mass spectrometry proteomics technologies are accelerating the discovery and validation of novel targets in cancer, opening up new avenues for next-generation cancer therapeutics.

Hear how the capabilities of mass spectrometry (MS)-based proteomics are proving themselves in drug development and discovery and what this means for those working in oncology.

At ASMS 2023, Technology Networks spoke with Jim Yano, senior director of product management at Thermo Fisher Scientific, to learn more about the company's novel instrument launches and how they could be applied to personalized medicine.

Unlocking more information from our proteome could deepen our understanding of disease, improve detection and influence drug selection. To find out more about single-molecule proteomics, we spoke to Parag Mallick, co-founder of Nautilus Biotech.